Page data last changed: . Registry refreshes and identity assessments are separate from scientific content review.
Broad inhibitory peptide; analogs like octreotide are clinic staples.
Part of the Foundational & therapeutic peptides cluster
Overview
Somatostatin is a 14-residue inhibitory peptide hormone regulating growth hormone and multiple gut/pancreatic hormones.
Source & context
Biological / chemical source: Hypothalamus, pancreas
Primary research or clinical context: Basis for analogs in neuroendocrine disease
Clinical analogs
Short half-life of native somatostatin drove development of octreotide, lanreotide, and pasireotide — a major peptide drug class.
Sequence of the selected reference form
Sequence backbone for the reference form: Human somatostatin-14, intramolecular Cys3-Cys14 disulfide. Termini, stereochemistry and modifications are described below.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Select the 14-residue mature human SST-14 molecule, including its native disulfide; this is a single explicitly named reference form of the somatostatin family.
- Molecular form
- Human somatostatin-14, intramolecular Cys3-Cys14 disulfide
- Species
- Homo sapiens
- Termini (N / C)
- Free alpha-amino group of L-alanine / Free L-cysteine carboxylic acid (-COOH)
Average reference mass · Molecular identity assessment: 2026-10-05
Reference policy updated: 2026-10-05
- PubChem PUG molecular properties and explicit molecular graph · 2026-10-05
- PubChem PUG stereochemistry and normalized structure identity · 2026-10-05
- Reviewed UniProt molecular sequence and processed-chain annotations · 2026-10-05
- Original MS study of somatostatin-14 disulfide connectivity · 2026-10-05
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH [Cys3-S-S-Cys14]
- Molecular formula
- C76H104N18O19S2
- Average reference mass
- ≈ 1,637.9
- Backbone
- Human somatostatin-14, intramolecular Cys3-Cys14 disulfide
- C-terminus
- Free L-cysteine carboxylic acid (-COOH)
- PubChem CID: 16129706
Chemistry values: curated profile, PubChem.
Clinical development snapshot
ClinicalTrials.gov lists 362 registered studies with “Somatostatin” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrin | Phase 1 | recruiting | 2026-10-01 |
| NCT06991738 | 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cel | Phase 2 | not yet recruiting | 2026-10-01 |
| NCT02743741 | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors | Not applicable | completed | 2026-09-29 |
| NCT04086485 | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine | Phase 2 | recruiting | 2026-09-28 |
| NCT06441331 | Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in P | Phase 1 | recruiting | 2026-09-25 |
| NCT07842172 | Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neu | Phase 3 | not yet recruiting | 2026-09-25 |
Somatostatin — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Human somatostatin-14, intramolecular Cys3-Cys14 disulfideAverage reference mass: 1,637.9 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
Change log
Dated observations from the data pipeline (registry flags, trial footprints, identifiers) and editorial reviews of this profile.
- ChemistryPubChem formula updated to C76H104N18O19S2.
- Trials3 registered studies added on ClinicalTrials.gov (now 362).
FAQ about Somatostatin
What is Somatostatin?+
Somatostatin is a 14-residue inhibitory peptide hormone regulating growth hormone and multiple gut/pancreatic hormones.
What Canadian product status is recorded for Somatostatin?+
Canadian product status for Somatostatin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the length of the selected reference form for Somatostatin?+
The selected reference form (Human somatostatin-14, intramolecular Cys3-Cys14 disulfide) has 14 residues or residue-derived units in its backbone. Other forms in this family may have a different length.
Related peptides
References & further reading
- 1.Janecka et al. (2001). Somatostatin analogs. J Pept Res
- 2.Gibril et al. (2004). Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis
- 3.Andrisani et al. (1990). Somatostatin gene regulation. Annu Rev Physiol
- 4.Arimura et al. (1981). Somatostatin: regulation of secretion. Neuroendocrinology
- 5.Liguz-Lecznar et al. (2016). Somatostatin and Somatostatin-Containing Neurons in Shaping Neuronal Activity and Plasticity. Front Neural Circuits
- 6.Reisine et al. (1995). Molecular properties of somatostatin receptors. Neuroscience
- 7.Chalabi et al. (2014). Somatostatin analogs: does pharmacology impact antitumor efficacy?. Trends Endocrinol Metab
- 8.Ben-Shlomo et al. (2017). Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. Pituitary
- 9.PubChem — compound summary for Somatostatin (CID 16129706)
- 10.Wikipedia — Somatostatin